via pharmatimes.com
The Irish government and the country's drugmakers have agreed interim drug price cuts which, they say, will deliver savings totalling 20 million euros in a full year and allow new products to be supplied through state drug schemes.
The new agreement extends the recently-expired deal between Ireland's Health Service Executive (HSE) and the Irish Pharmaceutical Healthcare Association (IPHA), under which, when a generic equivalent of an off-patent drug came onto the market, the price of the original product was reduced by 20% immediately and by a further 15% after 22 months.
No comments:
Post a Comment